How to buy CASI Pharmaceuticals stock (CASI)

CASI Pharmaceuticals is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.98 – an increase of 12.45% over the previous week. CASI Pharmaceuticals employs 176 staff and has a trailing 12-month revenue of around $23.1 million.

Our top picks for where to buy CASI Pharmaceuticals stock

Buy CASI Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

CASI Pharmaceuticals stock price (NASDAQ: CASI)

Use our graph to track the performance of CASI stocks over time.

CASI Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$2.98
52-week range	$2.05 - $8.19
50-day moving average more info button	$6.05
200-day moving average more info button	$5.00
Wall St. target price	$6.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.03

Is it a good time to buy CASI Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CASI Pharmaceuticals price performance over time

Historical closes compared with the close of $3.07 from 2024-12-26

1 week (2024-12-20)	15.85%
1 month (2024-11-29)	-19.21%
3 months (2024-09-27)	-48.92%
6 months (2024-06-28)	-44.18%

1 year (2023-12-28)	-57.30%
2 years (2022-12-28)	93.08%
3 years (2021-12-28)	8.379
5 years (2019-12-27)	31.9

CASI Pharmaceuticals financials

Revenue TTM	$23.1 million
Gross profit TTM	$17.6 million
Return on assets TTM	-26.6%
Return on equity TTM	-85.43%
Profit margin	-117.68%
Book value	$0.67
Market Capitalization more info button	$86.6 million

TTM: trailing 12 months

CASI Pharmaceuticals share dividends

We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.

Have CASI Pharmaceuticals's shares ever split?

CASI Pharmaceuticals's shares were split on a 1:10 basis on 1 June 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.

CASI Pharmaceuticals share price volatility

Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $2.05 up to $8.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.65. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).

CASI Pharmaceuticals overview

CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd. ; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc. ; and Acrotech Biopharma L.

Frequently asked questions

null
What percentage of CASI Pharmaceuticals is owned by insiders or institutions?
Currently 47.92% of CASI Pharmaceuticals shares are held by insiders and 24.223% by institutions. How many people work for CASI Pharmaceuticals?
Latest data suggests 176 work at CASI Pharmaceuticals. When does the fiscal year end for CASI Pharmaceuticals?
CASI Pharmaceuticals's fiscal year ends in December. Where is CASI Pharmaceuticals based?
CASI Pharmaceuticals's address is: 1701-1702, China Central Office Tower 1, Beijing, China, 100025 What is CASI Pharmaceuticals's ISIN number?
CASI Pharmaceuticals's international securities identification number is: US14757U1097 What is CASI Pharmaceuticals's CUSIP number?
CASI Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 29382F103